Drug Interaction Between Complementary Herbal Medicines and Gefitinib

Slides:

Advertisements

Similar presentations

The Accuracy of Frozen Section Diagnosis of Pulmonary Nodules: Evaluation of Inflation Method during Intraoperative Pathology Consultation with Cryosection.

Advertisements

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer Haa-Na Song, MD,

Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD

Sukki Cho, MD, Kyung-Min Ryu, MD, Yoon-Jin Hwang, MD, Eung Bae Lee, MD

Volume 30, Issue 2, Pages (August 1956)

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Lung Cancer with Unusual Presentation as a Thin-Walled Cyst in a Young Nonsmoker Chou-Chin Lan, MD, Hong-Cheng Wu, MD, Chih-Hsin Lee, MD, Shiu-Feng Huang,

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease Eisaku.

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung.

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer Haa-Na Song, MD,

David T. Cooke, MD, Dennis J. Zheng, Karen A. Peterson, NP, Royce F

OPG/RANKL/RANK Pathway as a Therapeutic Target in Cancer

Joachim Pfannschmidt, MD, Hans Hoffmann, MD, Hendrick Dienemann, MD

First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status Young Joo Lee, MD, Heung Tae Kim, MD,

A Novel Strategy for Treatment of Metastatic Pulmonary Tumors: Radiofrequency Ablation in Conjunction with Surgery Yoshifumi Sano, MD, Susumu Kanazawa,

Electronic Updates for JTO Readers

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer Hiroyasu Kaneda, MD, PhD, Isamu.

The Moth-Eaten Lung Journal of Thoracic Oncology

Successful Crizotinib Retreatment after Crizotinib-Induced Interstitial Lung Disease Satoru Yanagisawa, MD, PhD, Akira Inoue, MD, PhD, Akira Koarai, MD,

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Atypical Pleuropulmonary Tuberculosis Mimicking a Malignant Disease

Frank Detterbeck, MD Journal of Thoracic Oncology

Metastatic Angiosarcoma Arising From the Right Atrium: Unusual Presentation and Excellent Response to Treatment in a Young Patient Martin Fehr, MD, Max.

Multiple Pulmonary Chondromas in a Young Female Patient: A Component of Carney Triad Gui-Bin Qiao, MD, PhD, Wei-Sheng Zeng, MD, Li-Jun Peng, MD, Wen-Zhao.

Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease Masayuki Takeda, MD, PhD, Isamu Okamoto, MD, PhD, Chihiro.

Esophageal Ultrasound-Controlled Fine Needle Aspiration for Staging of Mediastinal Lymph Nodes in Patients with Resectable Lung Cancer: Do We Always See.

Effective Treatment with Icotinib in Primary Adenoid Cystic Carcinoma of the Lung with Liver Metastasis Zhengbo Song, MD, Wei Wu, MD, Yiping Zhang, MD

Evaluating Cryoablation of Metastatic Lung Tumors in Patients—Safety and Efficacy The ECLIPSE Trial—Interim Analysis at 1 Year Thierry de Baere, MD,

Lung Cancer Screening and Video-Assisted Thoracic Surgery

A New KIT Gene Mutation in Thymic Cancer and a Promising Response to Imatinib Sung Hee Lim, MD, Ji-Yun Lee, MD, Jong-Mu Sun, MD, PhD, Kyoung-Mee Kim,

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib Oana Pop, MD, Augustin Pirvu,

Primary repair of rupture of a main and lobar bronchus

A Different Method in Diagnosis of Multiple Primary Lung Cancer

A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib Yoon Jin Cha, MD, PhD, Byoung Chul.

The Role of Surgery in the Management of Primary Thymic Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Kimihiro Shimizu, MD, PhD, Izumi Takeyoshi,

Jennifer L. Dallas, MD, Michael A. Jantz, MD, Judith L

Nasion Swelling as the Presenting Symptom of Lung Adenocarcinoma

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

The Number of Pulmonary Metastases: Influence on Practice and Outcome

Multiple Primary Cancers or Multiple Metastases, That Is the Question

Shih-Chieh Chang, Cheng-Yu Chang, Chiung-Yu Chen, Chong-Jen Yu

Multiple Pulmonary Nodules in an Elderly Woman

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Two Generations of Light/Never-Smokers With Advanced Adenocarcinoma of the Lung with Durable Responses to Erlotinib Nathan A. Pennell, MD, PhD, Lihong.

Antiangiogenesis Induced Tumor Cavitation in Lung Cancer

European Lung Cancer Conference (ELCC) 2016 Organisation

Andreas Rimner, MD, Kenneth E. Rosenzweig, MD

Tetsuzo Tagawa, MD, Miyuki Takasu, MD, Teruyoshi Ishida, MD

Metastatic Lung Cancer to the Pancreas

S-1 Treatment for Chemorefractory Thymic Carcinoma

Follow-Up of Small (4 mm or Less) Incidentally Detected Nodules by Computed Tomography in Oncology Patients: A Retrospective Review Reginald F. Munden,

Intrathoracic Desmoid Tumor: Brief Report and Review of Literature

Pleural Metastases of Malignant Melanoma

Journal of Thoracic Oncology

Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation Yao-Wen Kuo, MD, Shang-Gin Wu, MD, Chao-Chi.

David Garfield, MD Journal of Thoracic Oncology

Popcorn in the Lung Journal of Thoracic Oncology

Lack of FDG Uptake in Small Cell Carcinoma Associated with ANNA-1 Positive Paraneoplastic Autonomic Neuropathy Matthew S. Block, MD, PhD, Robert Vassallo,

Patterns-of-Care for Thoracic Stereotactic Body Radiotherapy among Practicing Radiation Oncologists in the United States Megan E. Daly, MD, Julian R.

Randomized Phase II Study of Maintenance Irinotecan Therapy Versus Observation Following Induction Chemotherapy with Irinotecan and Cisplatin in Extensive.

Use of Fluoroscopy During Endobronchial Ultrasonography for Transbronchial Lung Biopsies of Peripheral Lung Lesions Daniel Steinfort, MBBS, Louis Irving,

A Review of First-Line Treatment for Small-cell Lung Cancer

Robert Comis, MD, The Passing of a “Lung Man”

Lung Cancer with Unusual Presentation as a Thin-Walled Cyst in a Young Nonsmoker Chou-Chin Lan, MD, Hong-Cheng Wu, MD, Chih-Hsin Lee, MD, Shiu-Feng Huang,

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Drug Interaction Between Complementary Herbal Medicines and Gefitinib Sung-Wook Hwang, MD, Hye-Suk Han, MD, Kun Young Lim, MD, Ji-Youn Han, MD, PhD Journal of Thoracic Oncology Volume 3, Issue 8, Pages 942-943 (August 2008) DOI: 10.1097/JTO.0b013e3181803f1e Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Chest CT before and after gefitinib treatment. Initial CT scan at the level of right lower lobar bronchus revealed a speculated mass with cavitary change in the right lower lobe suggesting primary lung cancer. Multiple hematogenous metastatic nodules with or without cavitary change were seen in both lungs (A). On CT scan obtained 9 weeks after gefitinib treatment, the primary mass in the right lower lobe and pulmonary metastases in both lungs were increased (B). On CT scan obtained 4 weeks after discontinuation of herbal medicines, primary mass and hematogenous metastatic nodules were markedly decreased (C). On CT scan obtained a total of 30 weeks after gefitinib treatment, the primary mass in the right lower lobe was further decreased (D). Journal of Thoracic Oncology 2008 3, 942-943DOI: (10.1097/JTO.0b013e3181803f1e) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions